The European generic pharmaceutical market in review: 2006 and beyond

Journal of Generic Medicines

Volumn 4, Issue 1, 2006, Pages 4-14

  Perry, Greg ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

COMPETITION; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SUBSTITUTION; EUROPE; EUROPEAN UNION; GOVERNMENT REGULATION; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE QUALITY; INFORMATION DISSEMINATION; PRESCRIPTION; REVIEW;

EID: 33846885207     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/palgrave.jgm.4950041     Document Type: Review

References (13)

1. Established in March 2001 by Erkki Liikanen, Commissioner for Enterprise, and David Byrne, Commissioner for Public Health.
2. G10 Medicines - High Level Group on Innovation and the Provision of Medicines, Final Report: Recommendations for Action, European Commission (7 May 2002), p. 14 (Available on-line at ec.europa.eu/health/ ph_overview/Documents/key08_en.pdf) 'Recommendation 4: To secure the development of a competitive generic market in Europe, that: The European Institutions agree a way forward on intellectual property rights issues (especially data exclusivity and Bolar) covered in the Commission's proposed legislation. Member States - facilitated by the Commission - explore ways of increasing generic penetration in individual markets (including generic prescribing and dispensing). Particular attention should be given to improved market mechanisms in full respect of public health considerations.
3. The Pharmaceutical Forum is chaired jointly by Commission vice-president Günter Verheugen, Commissioner for Enterprise and Industry, and Markos Kyprianou, Commissioner for Public Health and Consumer Protection. The Forum will consist of Ministers from all 25 EU Member States, Members of the European Parliament, and senior representatives from key stakeholder groups, including all sectors of the pharmaceutical industry (originator and generic), health insurance groups, patient representatives and healthcare professionals.
4. European Generic Medicines Association (EGA). 2005 Market Review The European Generics Pharmaceutical Markets, Internal EGA Document (June 2005).
5. See. Global Generics Market 80% Larger at US$68bn, Generics Bulletin, Issue 39 (7 October 2005), page 1.
6. Also see: IMS Announces Agreement with European Generic Medicines Association: IMS and EGA will Work Together to Assess, Support the Growing EU Generic Market, IMS Press Release (11 Nov 2004). Available on-line at: http://www.imshealth.com/ims/portal/front/articleC/ 0,2777,6599_3665_62451903,00.html.
7. European Generic Medicines Association (EGA). 2006 Market Review: The European Generics Pharmaceutical Markets, Internal EGA Document (May 2006).
8. Price Transparency Directive: Directive 89/105/EEC. Available on-line at: Pharmacos.eudra.org/F2/eudralex/vol-1/DIR_1989_105/ DIR_1989_105_EN.pdf.
9. G10 Medicines, p. 13. 'Recommendation 3: Respecting national competence, Member States should examine the scope for improving time taken between the granting of a marketing authorisation and pricing and reimbursement decisions in full consistency with Community legislation. To do this with a view to securing greater uniformity and transparency between markets and rapid access of patients to medicines'.
10. Simoens, S. & De Coster, S. (2006) Sustaining Generic Medicines Markets in Europe, Research Centre for Pharmaceutical Care and Pharmaco-economics, University of Leuven (April). Available on-line at: www.egagenerics.com/doc/simoens-report_2006-04.pdf.
11. See Bibliography in: Simoens, op. cit., p. 97-102.
12. Simoens, op. cit., p. 10. See also page 66.
13. Simoens, op. cit., p. 10. See also page 66.